STOCK TITAN

Nuvation Bio (NUVB) director awarded 123,397 stock options at $4.79

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Nuvation Bio Inc. director Kathryn E. Falberg received a grant of stock options covering 123,397 shares of Class A common stock at an exercise price of $4.79 per share. The options vest 100% on the earlier of May 21, 2026 or the next shareholder annual meeting, subject to her continuous service, and expire on May 20, 2036. Following this award, she holds 123,397 derivative securities directly.

Positive

  • None.

Negative

  • None.
Insider FALBERG KATHRYN E
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 123,397 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 123,397 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 123,397 options Stock Option (Right to Buy) granted to director on May 21, 2026
Exercise price $4.79 per share Conversion or exercise price for Class A common stock
Post-grant derivative holdings 123,397 derivative securities Total options held directly following the transaction
Vesting date trigger May 21, 2026 100% vesting on earlier of this date or next annual meeting
Expiration date May 20, 2036 Option award expiration date
Transaction price per option $0.00 Grant/award acquisition, no cash paid for options
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Class A Common Stock financial
"underlying_security_title: Class A Common Stock"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
exercise price financial
"conversion_or_exercise_price: 4.7900"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-05-20T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
grant date financial
"one-year anniversary of the grant date (May 21, 2026)"
The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.
continuous service financial
"subject to the Reporting Person's continuous service through such applicable vesting date"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
FALBERG KATHRYN E

(Last)(First)(Middle)
C/O NUVATION BIO INC.
1500 BROADWAY, SUITE 1401

(Street)
NEW YORK NEW YORK 10036

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Nuvation Bio Inc. [ NUVB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$4.7905/21/2026A123,397 (1)05/20/2036Class A Common Stock123,397$0123,397D
Explanation of Responses:
1. 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 21, 2026); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date.
/s/ Stephen Dang, Attorney-in-Fact05/26/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Nuvation Bio (NUVB) director Kathryn Falberg report in this Form 4?

Kathryn E. Falberg reported receiving a stock option grant for 123,397 shares of Nuvation Bio Class A common stock. The options were awarded as compensation, not bought in the open market, and give her the right to purchase shares at a fixed exercise price.

How many Nuvation Bio (NUVB) options were granted to Kathryn Falberg?

She was granted options on 123,397 underlying shares of Class A common stock. This entire amount represents a new award, and after the transaction she holds 123,397 derivative securities directly according to the Form 4 disclosure for this grant.

What is the exercise price of Kathryn Falberg’s Nuvation Bio (NUVB) stock options?

The stock options have an exercise price of $4.79 per share. This means she can buy Nuvation Bio Class A common stock at $4.79 for each optioned share once the options vest and before they reach their stated expiration date.

When do Kathryn Falberg’s Nuvation Bio (NUVB) options vest?

One hundred percent of the options vest on the earlier of May 21, 2026 or the next shareholder annual meeting. Vesting is conditioned on her continuous service through the applicable vesting date, as specified in the footnote to the Form 4 filing.

When do Kathryn Falberg’s Nuvation Bio (NUVB) options expire?

The options expire on May 20, 2036, giving a long-term window to exercise after vesting. After that expiration date, any unexercised options will lapse, and she will no longer have the right to purchase shares under this particular award.

Was Kathryn Falberg’s Nuvation Bio (NUVB) transaction a market purchase or sale?

The transaction was a grant of stock options, not a market purchase or sale. The Form 4 shows a transaction code "A" for a grant or award acquisition, with a transaction price per option of $0.00 and a fixed exercise price of $4.79 per share.